JP2019510830A - がん処置における改善 - Google Patents

がん処置における改善 Download PDF

Info

Publication number
JP2019510830A
JP2019510830A JP2019503595A JP2019503595A JP2019510830A JP 2019510830 A JP2019510830 A JP 2019510830A JP 2019503595 A JP2019503595 A JP 2019503595A JP 2019503595 A JP2019503595 A JP 2019503595A JP 2019510830 A JP2019510830 A JP 2019510830A
Authority
JP
Japan
Prior art keywords
defined above
base
cor
composition according
suppository
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019503595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510830A5 (enExample
Inventor
ケリー グレイアム
ケリー グレイアム
Original Assignee
ノクソファーム リミティド
ノクソファーム リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノクソファーム リミティド, ノクソファーム リミティド filed Critical ノクソファーム リミティド
Publication of JP2019510830A publication Critical patent/JP2019510830A/ja
Publication of JP2019510830A5 publication Critical patent/JP2019510830A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019503595A 2016-04-06 2016-07-28 がん処置における改善 Pending JP2019510830A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
US62/318,946 2016-04-06
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment

Publications (2)

Publication Number Publication Date
JP2019510830A true JP2019510830A (ja) 2019-04-18
JP2019510830A5 JP2019510830A5 (enExample) 2019-09-05

Family

ID=60000141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503595A Pending JP2019510830A (ja) 2016-04-06 2016-07-28 がん処置における改善

Country Status (11)

Country Link
US (2) US20190160004A1 (enExample)
EP (2) EP3939583A1 (enExample)
JP (1) JP2019510830A (enExample)
KR (1) KR20190016017A (enExample)
CN (1) CN109475522A (enExample)
AU (2) AU2016401508B2 (enExample)
CA (1) CA3058479A1 (enExample)
IL (1) IL262143A (enExample)
RU (1) RU2018137897A (enExample)
SG (1) SG11201808777UA (enExample)
WO (1) WO2017173474A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513826A (ja) * 2016-04-06 2019-05-30 ノクソファーム リミティド 放射線療法の改善
CA3058503A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
JP2023519990A (ja) 2020-03-30 2023-05-15 ノクソファーム リミティド 感染に関連する炎症の治療のための方法
WO2022204757A1 (en) * 2021-03-30 2022-10-06 Noxopharm Limited Improved isoflavone formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504705A (ja) * 2002-10-02 2006-02-09 ノボジェン リサーチ プロプライアタリー リミテッド 併用化学療法組成物および方法
JP2006504409A (ja) * 2002-07-24 2006-02-09 チルドレンズ　ホスピタル　メディカル　センター 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法
JP2009508869A (ja) * 2005-09-15 2009-03-05 ユーエムディー， インコーポレイテッド シトクロムｐ４５０についての基質活性を持つ上皮内及び全体的な曝露の増大のための方法、及び膜流出系それに次ぐ鞘及び口腔の管理

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
JP2007525485A (ja) 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
DE102005009515A1 (de) * 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
US20110166142A1 (en) * 2007-06-29 2011-07-07 Eleanor Eiffe 2-substituted isoflavonoid compounds, medicaments and uses
EP2334296A4 (en) * 2008-08-29 2012-04-25 Novogen Res Pty Ltd IMMUNOMODULATING ACTIVITIES
KR20110004525A (ko) * 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504409A (ja) * 2002-07-24 2006-02-09 チルドレンズ　ホスピタル　メディカル　センター 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法
JP2006504705A (ja) * 2002-10-02 2006-02-09 ノボジェン リサーチ プロプライアタリー リミテッド 併用化学療法組成物および方法
JP2009508869A (ja) * 2005-09-15 2009-03-05 ユーエムディー， インコーポレイテッド シトクロムｐ４５０についての基質活性を持つ上皮内及び全体的な曝露の増大のための方法、及び膜流出系それに次ぐ鞘及び口腔の管理

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 707, JPN6021002188, 1982, pages 273 - 279, ISSN: 0004432437 *
FOOD CHEMISTRY, vol. 62, no. 1, JPN6020017557, 1998, pages 73 - 97, ISSN: 0004273867 *
科学研究費助成事業（基盤研究（S））公表用資料 生体膜脂肪酸鎖の細胞生物学的機能, JPN6021002189, 2014, pages 1 - 2, ISSN: 0004432438 *

Also Published As

Publication number Publication date
RU2018137897A3 (enExample) 2020-05-13
EP3439651A4 (en) 2019-10-30
IL262143A (en) 2018-11-29
SG11201808777UA (en) 2018-11-29
AU2020204172A1 (en) 2020-07-09
RU2018137897A (ru) 2020-05-13
WO2017173474A1 (en) 2017-10-12
EP3939583A1 (en) 2022-01-19
CN109475522A (zh) 2019-03-15
KR20190016017A (ko) 2019-02-15
AU2016401508A1 (en) 2018-11-01
AU2016401508B2 (en) 2020-03-26
EP3439651A1 (en) 2019-02-13
CA3058479A1 (en) 2017-10-12
US20190160004A1 (en) 2019-05-30
US20210338576A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
US20210338576A1 (en) Cancer treatment
CN101583606A (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
WO2007056941A1 (fr) Utilisation de composes a base d'isothiocyanates dans le traitement de maladies prostatiques et du cancer de la peau
TWI422377B (zh) 用於促進抗癌治療活性之方法及組成物
JP2021169534A (ja) 化学療法の改善
EP3429568A1 (fr) Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications
EP3439644B1 (en) Isoflavonoid composition with improved pharmacokinetics
TW200412986A (en) Novel dammarane sapogenins,their use as anti-cancer agents, and a process producing same
CN113082039B (zh) 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用
JP2023516236A (ja) 癌の予防または治療用薬学組成物
CN102441168A (zh) 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用
CN107583054A (zh) 隐丹参酮药物组合物及其在制备治疗慢性粒细胞白血病药物中的应用
HK40006250A (en) Improvements in cancer treatment
JP2019513827A (ja) 標的化薬物送達
CN102526033B (zh) 由表没食子儿茶素没食子酸酯与丝裂霉素c制成的抑制肿瘤细胞增殖的组合物
WO2015021922A1 (zh) 人参皂苷Rd或其肠溶制剂及用途
HK1138797A (zh) 肝癌治疗剂
CN101610771A (zh) 肝癌治疗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210928